Cornerstone Robotics' Sentire won EU clearance under the Medical Device Regulation, the stricter successor to the old directive. The leverage that creates for European hospitals is the real story.
European surgical chiefs and hospital procurement teams just gained a new kind of leverage for the first time in a generation. On May 25, Cornerstone Robotics announced that its Sentire Endoscopic Surgical System received CE mark certification under the European Union's Medical Device Regulation (MDR), covering general surgery, gynecology, thoracic surgery, and urology. The clearance is permission to compete in a market that has belonged almost entirely to Intuitive Surgical's da Vinci for 25 years. Whether it becomes actual competition is a separate question, and one that European hospitals, not Cornerstone's press releases, will answer.
The regulatory label is the part that matters most. Sentire's CE mark is issued under the Medical Device Regulation, the framework that succeeded the older Medical Device Directive in the EU and that requires substantially more clinical evidence, traceability, and post-market surveillance than the system it replaced. A 2026 MDR clearance sits on a different shelf than legacy CE marks held by older surgical robots. Cornerstone is cleared to enter Europe under the stricter gate. The question is what it does with the access.
The clinical evidence so far is real, but narrow. A peer-reviewed prospective study published in the Hong Kong Medical Journal (Ng et al., 2025) followed 20 men who underwent robot-assisted radical prostatectomy using the Sentire C1000 between August 2022 and September 2023. None of the cases converted to open surgery. None had device-related intraoperative complications. The mean operative time was 184.5 minutes, and 17 of 20 patients had undetectable PSA at one month. The surgeons in the study also noted that Sentire's hand controls and foot pedals closely mirror the da Vinci interface, a deliberate design choice that lowers the learning curve for surgeons already trained on Intuitive's system.
The European foothold is more concrete than a typical regulatory announcement. Cornerstone has run a clinical investigation in the United Kingdom since 2025 with Portsmouth Hospitals University NHS Trust. Jim Khan, the chief investigator and a colorectal surgeon, said his team adapted quickly during the first three procedures, which MedTech Dive reported covered urology, gynecology, and upper and lower gastrointestinal surgery. The company established the UK subsidiary in 2025 to support the European push, and it operates a roughly 30,000 square meter manufacturing facility in China with reported capacity of about 200 systems per year, according to a 2024 South China Morning Post interview with founder and CEO Samuel Au.
The financial plumbing is also in place. In November 2025, Cornerstone closed an oversubscribed round of about US$200 million, per the company's press release, with UBS as financial advisor. The investor list as disclosed names a single "global strategic investor" alongside unnamed "global institutional or sovereign wealth funds." Earlier, the company raised a $70 million Series C in January 2025, and a MedTech Dive profile puts total funding since the 2019 founding in the $200 million-plus range.
What Cornerstone has not done is name a price. In the SCMP interview, Au claimed performance "equivalent to the state-of-the-art" at "substantially lower" prices than da Vinci, a posture that matters because the Hong Kong Medical Journal paper itself frames Intuitive's system as carrying high acquisition, maintenance, and per-procedure disposable costs that have limited adoption in lower- and middle-income markets. "Substantially lower" is a CEO's framing, though, not a procurement officer's line item, and Cornerstone has not published a Sentire price list.
The harder question is the moat, not the regulatory clearance. Intuitive Surgical's da Vinci installed base in Europe runs into the thousands of systems, supported by roughly 25 years of clinical evidence, surgeon training pipelines, and a service infrastructure that competitors can read about but not replicate on a press-release timeline. Cornerstone's 20-patient prostatectomy series is a starting dataset, not a body of evidence. Surgeon training for robotic prostatectomy, gynecology, and thoracic procedures is built around da Vinci workflows. Hospital procurement decisions on capital equipment typically run on five-to-ten-year cycles, anchored by service contracts, training commitments, and the published outcomes of prior cases.
The 2025 milestones the company has flagged are demonstrations rather than deployments. MedTech Dive reported what the company called the first multi-site, living and intercontinental robotic telesurgery using Sentire, plus demonstrations of AI-enabled autonomous task execution including gauze picking. Both are company claims pending independent coverage, and neither substitutes for the multi-site clinical publications a European procurement committee will eventually want to read.
What changes today is leverage. A second credible vendor with MDR clearance, an in-progress UK clinical program, and disclosed manufacturing capacity gives European surgical chiefs a benchmark for the next da Vinci contract negotiation, a candidate to pilot in a single specialty, and a reason to ask training program directors what a second robotic platform would do to fellowship curricula. None of that is a market share number. All of it is something a European hospital can act on.
What to watch over the next 12 to 18 months: independent, non-company-affiliated clinical publications from the Portsmouth program and from any additional European sites; the first named European distributor or hospital contract; the first disclosed Sentire price against a comparable da Vinci configuration; and whether training fellowships begin offering Sentire as a primary or secondary platform. Until those land, the Sentire CE mark is a serious step. It is not, on its own, a market shift.